The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Biomarkers of cardiotoxicity in multiple myeloma
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY talks about the biomarkers of cardiotoxicity in multiple myeloma (MM). In this new era of more efficient therapies, the medical community is focusing on improving the quality of life of MM patients. Recent research has shown the detrimental impact of certain therapies on the cardiovascular system. Prof. Landgren discusses the data presented at the American Society of Hematology (ASH) 2015 Annual Meeting by his group on cardio-oncology in MM.
